Keyphrases
Multiple Sclerosis
100%
Migraine
76%
Headache
56%
Alzheimer's Disease
45%
Dementia
31%
Denmark
28%
Placebo
28%
Calcitonin Gene-related Peptide
27%
Healthy Controls
26%
Cerebrospinal Fluid
25%
Migraine without Aura (MWoA)
23%
Confidence Interval
23%
Traumatic Brain Injury
20%
Relapsing-remitting multiple Sclerosis
19%
Positron Emission Tomography
19%
Migraine Attack
18%
Multiple Sclerosis Treatment
18%
Cluster Headache
18%
Meta-analysis
17%
Magnetic Resonance Imaging
15%
Migraine Treatment
14%
Functional Magnetic Resonance Imaging
14%
Cerebral Blood Flow
13%
Tension-type Headache
13%
Healthy Volunteers
12%
Europe
12%
Frontotemporal Dementia
12%
Disability
12%
Major Depressive Disorder
12%
Receptor Binding
12%
Odds Ratio
12%
Serotonin 2A Receptor (5-HT2AR)
11%
Medication Overuse Headache
11%
Cognitive Impairment
11%
Bipolar Disorder
11%
Randomized Controlled Trial
11%
Mild Cognitive Impairment
11%
Ischemic Stroke
11%
Healthy Individuals
11%
Disease-modifying Therapy
10%
Progressive multiple Sclerosis
10%
Risk Factors
10%
McArdle Disease
10%
Placebo-controlled
10%
Migraine Patients
10%
Huntington's Disease
10%
Chronic Migraine
10%
Single-photon Emission Computed Tomography (SPECT)
10%
Idiopathic Intracranial Hypertension
10%
Systematic Meta-analysis
10%
Clinical Trials
10%
Epilepsy
9%
National Cohort Study
9%
Optic Neuritis
9%
Neurotrauma
9%
Memory Clinic
9%
5-HT2A Receptor
9%
Effectiveness Research
9%
Neurodegenerative Diseases
9%
Radioligand
9%
Diagnostic Criteria
8%
Hippocampus
8%
Genome-wide Association Study
8%
Sumatriptan
8%
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)
8%
Serotonin Transporter
8%
Dementia Diagnosis
8%
Quality of Life
8%
Erenumab
8%
Comorbidity
8%
Natalizumab
8%
Disease Activity
8%
Migraine-like
8%
Pathophysiology
7%
Preventive Treatment
7%
Randomized Placebo-controlled Trial
7%
Primary Headache
7%
Cerebrospinal Fluid Biomarkers
7%
5-hydroxytryptamine
7%
Episodic Migraine
7%
Non-associated
7%
Intracranial Pressure
7%
Adverse Events
7%
Hazard Ratio
7%
Cognitive Function
7%
COVID-19
7%
Interferon-β (IFN-β)
7%
Regional Cerebral Blood Flow (rCBF)
7%
Randomized Clinical Trial
7%
Global Burden of Disease Study
7%
Induced Pluripotent Stem Cells (iPSCs)
7%
Migraine Prevention
7%
During Exercise
7%
Neurofilament Light (NF-L)
6%
Myasthenia Gravis
6%
Mild Alzheimer's Disease
6%
Clinical Practice
6%
Schizophrenia
6%
Diabetic Nephropathy
6%
Triptans
6%
Medicine and Dentistry
Migraine
57%
Headache
44%
Multiple Sclerosis
42%
Disease
34%
Apoplexy
28%
Magnetic Resonance Imaging
26%
Symptom
25%
Diagnosis
23%
Systematic Review
19%
Placebo
19%
Traumatic Brain Injury
16%
Alzheimer's Disease
15%
Cohort Analysis
14%
Biological Marker
14%
Calcitonin Gene Related Peptide
13%
Prevalence
13%
Brain Ischemia
11%
Drug Therapy
11%
Brain Blood Flow
11%
Cerebrospinal Fluid
10%
Meta-Analysis
10%
Tension Headache
10%
Cluster Headache
9%
Glycogen Storage Disease Type V
9%
Myopathy
8%
Randomized Controlled Trial
8%
Artery
7%
Clinical Trial
7%
Migraine with Aura
7%
Medication Overuse Headache
7%
Nervous System Injury
7%
Positron Emission Tomography
7%
Global Disease Burden
7%
Idiopathic Intracranial Hypertension
6%
Pathophysiology
6%
Injury
6%
Quality of Life
6%
Odds Ratio
6%
Auras
6%
Prophylaxis
6%
Pediatrics
6%
Case-Control Study
5%
Epileptic Seizure
5%
Exercise
5%
Infusion
5%
Neurologic Disease
5%
Transformed Migraine
5%
Atrial Fibrillation
5%
Muscle Strength
5%
Adverse Event
5%
Trigeminal Neuralgia
5%
Observational Study
5%
Headache and Facial Pain
5%
Neurology
5%
COVID-19
5%
Intracranial Pressure
5%
Erenumab
5%
Migraine without Aura
5%
Cross Sectional Study
5%
Cerebral Hemorrhage
5%
Functional Magnetic Resonance Imaging
5%